KIN
$3.98
Kindred Biosciences
KIN
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($0.41)
Revenue:  $1.75 Mil
Monday
Jun 15
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when KIN reports earnings?
Beat
Meet
Miss

Where is KIN's stock price going from here?
Up
Flat
Down
Stock chart of KIN
Analysts
Summary of analysts' recommendations for KIN
Score
Grade
Pivots
Resistance
$4.67
$4.50
$4.24

$4.07

Support
$3.81
$3.64
$3.38
Tweet
Growth
Description
Kindred Biosciences, Inc. is a biopharmaceutical company which focuses on the development of therapies for pets. The company provides small molecules and biologics that are in various stages of development for a range of indications in dogs, cats and horses. Kindred Biosciences, Inc. is based in Burlingame, California.
Peers
Heska